# Rare variant associations with birth weight identify genes involved in adipose tissue regulation, placental function and insulin-like growth factor signalling

4

Katherine A. Kentistou<sup>\*1</sup>, Brandon E. M. Lim<sup>\*2</sup>, Lena R. Kaisinger<sup>\*1</sup>, Valgerdur
Steinthorsdottir<sup>3</sup>, Luke N Sharp<sup>2</sup>, Kashyap A. Patel<sup>2</sup>, Vinicius Tragante<sup>3</sup>, Gareth
Hawkes<sup>2</sup>, Eugene J. Gardner<sup>1</sup>, Thorhildur Olafsdottir<sup>3</sup>, Andrew R. Wood<sup>2</sup>, Yajie Zhao<sup>1</sup>,
Gudmar Thorleifsson<sup>3</sup>, Felix R. Day<sup>1</sup>, Susan E. Ozanne<sup>6</sup>, Andrew T. Hattersley<sup>2</sup>,
Stephen O'Rahilly<sup>6</sup>, Kari Stefansson<sup>3,4</sup>, Ken K. Ong<sup>\*1,5</sup>, Robin N. Beaumont<sup>\*2</sup>, John R.
B. Perry<sup>\*1,6</sup>, Rachel M. Freathy<sup>\*2</sup>

- 11
- **12 1.** MRC Epidemiology Unit, Box 285 Institute of Metabolic Science, University of Cambridge
- 13 School of Clinical Medicine, Cambridge CB2 0QQ, UK
- **2.** Department of Clinical and Biomedical Sciences, Faculty of Health and Life Sciences,
- 15 University of Exeter, Exeter, UK
- **3.** deCODE genetics/Amgen, Inc., 102 Reykjavik, Iceland
- 17 4. Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland
- **5.** Department of Paediatrics, University of Cambridge, Cambridge CB2 0QQ, UK
- **6.** MRC Metabolic Diseases Unit, Institute of Metabolic Science, University of Cambridge
- 20 School of Clinical Medicine, University of Cambridge, Cambridge CB2 0QQ, UK
- \* These authors contributed equally to this work.

#### 22 Abstract

Investigating the genetic factors influencing human birth weight may lead to biological 23 insights into fetal growth and long-term health. Genome-wide association studies of birth 24 weight have highlighted associated variants in more than 200 regions of the genome, but the 25 causal genes are mostly unknown. Rare genetic variants with robust evidence of association 26 are more likely to point to causal genes, but to date, only a few rare variants are known to 27 influence birth weight. We aimed to identify genes that harbour rare variants that impact birth 28 weight when carried by either the fetus or the mother, by analysing whole exome sequence 29 data in UK Biobank participants. 30

31

We annotated rare (minor allele frequency <0.1%) protein-truncating or high impact missense 32 variants on whole exome sequence data in up to 234,675 participants with data on their own 33 34 birth weight (fetal variants), and up to 181,883 mothers who reported the birth weight of their first child (maternal variants). Variants within each gene were collapsed to perform gene 35 burden tests and for each associated gene, we compared the observed fetal and maternal 36 effects. We identified 8 genes with evidence of rare fetal variant effects on birth weight, of 37 which 2 also showed maternal effects. One additional gene showed evidence of maternal 38 effects only. We observed 10/11 directionally concordant associations in an independent 39 sample of up to 45,622 individuals (sign test P=0.01). 40

41

Of the genes identified, *IGF1R* and *PAPPA2* (fetal and maternal-acting) have known roles in insulin-like growth factor bioavailability and signalling. *PPARG, INHBE* and *ACVR1C* (all fetal-acting) have known roles in adipose tissue regulation and rare variants in the latter two also showed associations with favourable adiposity patterns in adults. We highlight the dual role of *PPARG* in both adipocyte differentiation and placental angiogenesis. *NOS3, NRK,* and *ADAMTS8* (fetal and maternal-acting) have been implicated in both placental function and hypertension.

49

50 Analysis of rare coding variants has identified regulators of fetal adipose tissue and 51 fetoplacental angiogenesis as determinants of birth weight, as well as further evidence for the 52 role of insulin-like growth factors.

# 53 Introduction

An improved understanding of the genetic contribution to birth weight may highlight 54 mechanisms relevant to fetal growth restriction or overgrowth, as well as links between fetal 55 growth and later disease<sup>1</sup>. Studies of rare, monogenic forms of diabetes have highlighted the 56 key role of fetal insulin, since rare single gene mutations in the fetus that reduce insulin 57 secretion are generally associated with a reduced birth weight. These include mutations that 58 cause neonatal diabetes, where the severity of the insulin secretory defect correlates with the 59 degree of reduction in birth weight<sup>2</sup>. In babies who produce no insulin at all due to pancreatic 60 agenesis, or to complete loss-of-function (LoF) mutations in the insulin gene, birth weights 61 are 50% of those of a healthy term baby<sup>3</sup>. 62

63

Family studies of mutations in the GCK gene have demonstrated the role of maternal genetic 64 variants, which may influence birth weight independently of variants inherited by the fetus. 65 Maternal heterozygous mutations in GCK, which reduce glucose sensing and cause fasting 66 glucose to be regulated at a higher set-point, result in greater maternal glucose availability to 67 the fetus, as glucose crosses the placenta. This causes the fetus, if it does not carry the 68 mutation, to produce more fetal insulin and grow bigger in response<sup>4</sup>. Conversely, if the fetus 69 carries a GCK mutation, its ability to sense the increase in glucose is impaired, causing 70 reduced fetal insulin secretion and concomitant reduced fetal growth. 71

72

73 Genome-wide association studies of birth weight have identified >200 regions of the genome where common variants (minor allele frequency (MAF) >1%) are associated with birth 74 weight<sup>5.6</sup>. Variants at the identified loci influence birth weight by direct effects of the fetal 75 genotype, indirect effects of the maternal genotype acting on the intrauterine environment, or 76 a combination of the two. Most of these variants likely influence growth via mechanisms that 77 are independent of fetal insulin secretion<sup>7</sup>. Parent-of-origin effects in the fetus have been 78 observed at several birth weight loci<sup>6</sup>. However, the causal genes at the vast majority of 79 identified loci are unknown. 80

81

Whole exome sequence (WES) data in biobank-scale studies offer the opportunity to identify 82 genes that are causally related to birth weight, and the potential to uncover new mechanisms 83 of importance for the regulation of fetal growth. We performed exome-wide association 84 studies (ExWAS) of rare variant (MAF < 0.01) gene burden with birth weight in up to 234,675 85 UK Biobank participants who reported their own birth weight (fetal variants), and up to 86 181,883 female UK Biobank participants who reported the birth weight of their first child 87 (maternal variants). The identified genes highlight key roles for adipose tissue regulation and 88 89 fetoplacental angiogenesis, in addition to the role of insulin-like growth factor bioavailability 90 and signalling, in regulating human birth weight.

## 91 Results

We identified 8 genes in which rare (MAF<0.1%) deleterious LoF fetal variants, defined as</li>
 either high-confidence protein truncating variants, or missense variants with a CADD score

>=25. were associated with birth weight at exome-wide significance (BOLT-LMM 94 P<1.64×10<sup>-6</sup>): ACVR1C, IGF1R, INHBE, NOS3, NRK, NYNRIN, PAPPA2, PPARG (Figure 1, 95 Supplementary Figures 1-3, Supplementary Table 1). In the analysis of maternal variants 96 and offspring birth weight, 3 genes showed associations at exome-wide significance 97 (BOLT-LMM P<1.58×10<sup>-6</sup>). These included 2 genes also identified in the fetal analysis 98 (IGF1R, NOS3) and additionally ADAMTS8 (Figure 1, Supplementary Figures 4-5, 99 **Supplementary Table 1**). We also confirmed all of these significant associations by 100 conducting independent analyses using REGENIE (see Methods) and we did not observe 101 any method-related biases (Supplementary Figures 1, Supplementary Table 1). 102



Figure 1 | Exome-wide rare (MAF<0.1%) fetal or maternal variant gene burden 103 associations with birth weight. (a) Miami plot showing gene burden test results from 104 BOLT-LMM for birth weight, with the fetal exome-wide analysis (up to n=234,675) on the top 105 panel and the maternal exome-wide analysis (up to n=181,883) on the bottom panel. Gene 106 associations passing exome-wide significance, at  $P < 1.64 \times 10^{-6}$  in the fetal analysis and 107  $P < 1.58 \times 10^{-6}$  in the maternal analysis, are labelled. The two variant collapsing masks are 108 indicated by point shapes. (b) QQ plots for exome-wide gene burden associations. Results 109 for the exome-wide significant genes are included in Supplementary Table 1. 110

111

Since maternal and fetal genotypes are correlated (r=0.5), we explored whether the observed 112 associations represented fetal effects, maternal effects, or both. To do this, we used a 113 weighted linear model (WLM) to approximately condition the fetal effect on the maternal 114 genotype, and vice versa. Five out of nine associations (ACVR1C, INHBE, NRK, NYNRIN, 115 PPARG) showed evidence of only fetal-genotype effects. IGF1R, PAPPA2, and NOS3 were 116 classified as both fetal- and maternal-acting, with rare variants in all three genes associating 117 with a lower birth weight in both cases. ADAMTS8 was the only gene classified as only 118 119 maternal-acting (Figure 2a, Supplementary Table 2). 120

For fetal genes associated with birth weight, we explored whether they might act in a sex-specific manner. We found a nominally stronger effect for fetal *PPARG* variants on birth weight in females (beta<sub>Female</sub>=-1.710 [0.340] SDs) than in males (beta<sub>Male</sub>=-0.177 [0.592] SDs,  $p_{het}=2.46 \times 10^{-02}$ ), albeit only 3 male carriers were identified (**Figure 2b**, **Supplementary Table** 3).



#### 126

Figure 2 | Nine genes with rare variant associations with birth weight. (a) 127 Weighted-linear models (WLMs) approximately conditioned the fetal effect on the maternal 128 genotype, and vice versa. Marker opacity indicates gene burden associations at P<0.05. (b) 129 Sexually-dimorphic effects of the associated genes on birthweight. Markers are coloured 130 yellow or red to indicate female- or male-only models. Marker opacity indicates associations 131 with sexual dimorphism (P<0.05). Units for effect estimates and accompanying 95% CIs are 132 SDs in both panels. Relevant data are included in Supplementary Tables 2 and 3, 133 accordingly. 134

#### 135 Confirmation of exome associations

We aimed to replicate our associations in independent data on up to 45,622 Icelandic genomes. Despite the substantially smaller sample size than our discovery sample, we observed supportive evidence for the same type of rare LoF exome variants on birth weight

for the majority of our associations (10/11 showed directional consistency; Sign test P=0.01), with three genes associated at P<0.05; *INHBE*, *NRK* and *PAPPA2* (**Supplementary Figure**)

#### **141 6**, Supplementary Table 4).

142

To identify whether any of the birth weight genes identified in our exome analyses are also 143 supported by common variant associations, we examined the latest maternal and fetal GWAS 144 summary statistics for birth weight<sup>6</sup> and looked for GWAS signals within 500kb of our 145 identified genes. We observed fetal GWAS signals proximal to ACVR1C, IGF1R, and 146 PAPPA2, and there was also a maternal GWAS signal proximal to NOS3 (Supplementary 147 Figure 7). In all cases the lead associated variants were located within these genes 148 (Supplementary Table 5) and proximity has been shown to be a good predictor of the causal 149 gene at a GWAS locus<sup>8,9</sup>. The lead SNPs at the *IGF1R* and *NOS3* loci were also eQTLs for 150 these genes, with directions of effect concordant with the exome associations, i.e. the alleles 151 associated with lower expression (LoF-like) were also associated with lower birth weight<sup>10</sup>. Of 152 these four GWAS signals, IGF1R, ACVR1C, and PAPPA2 were classified as having fetal only 153 effects by Juliusdottir et al.6. The SNP near NOS3 was not classified by Juliusdottir et al.6, but 154 the NOS3 lead SNP was classified by Warrington et al.<sup>5</sup> as having only maternal effects. We 155 did not observe attenuation of the rare variant associations with birth weight when 156 conditioning on the proximal GWAS sentinel SNPs (Supplementary Table 6). Hence, these 157 common variant associations provide independent support for these genes in the regulation 158 of birth weight. 159

160

To assess evidence for additional candidate genes influencing birth weight at GWAS loci. 161 which did not pass our stringent exome-wide significance thresholds, we looked at all genes 162 within 300 kb of a reported GWAS locus and applied a Benjamini-Hochberg correction for 163 multiple testing. The results are shown in Supplementary Table 7. In the fetal variant 164 analysis we identified a further eight candidate genes (CDK6, HGS, PAPPA, PHF19, PLAG1, 165 PLCE1, PTEN and SKP2), and in the maternal variant analysis we identified one additional 166 candidate gene (LMNA). At six of these genes (CDK6, PAPPA, PHF19, PLAG1, PLCE1 and 167 SKP2) a GWAS lead SNP was located within the same gene, while the lead SNP within 168 PLCE1 was also a missense variant, further adding to the evidence that non-synonymous 169 coding variation in these genes affects birth weight. 170

171

Finally, we explored whether the biology implicated by the exome-associated genes was 172 consistent with that from GWAS studies. To do this, we performed a pathway enrichment 173 analysis, using genes proximal to the GWAS signals from Juliusdottir et al.<sup>6</sup>. We saw 174 enrichment for 185 GO pathways in the fetal GWAS of birth weight and 41 pathways in the 175 maternal GWAS, with 21 pathways being enriched in both GWAS (fetal and maternal, 176 177 **Supplementary Table 8).** In line with biology implicated by our exome associations, we observed significant enrichment for genes in multiple pathways implicated in insulin and 178 growth factor response across both fetal and maternal GWAS genes and "circulatory system 179 180 development" for fetal GWAS genes, among others.

#### 181 Gene burden associations with related traits

To understand the wider phenotypic impacts of birth weight-associated rare genomic variation, we performed phenotypic association lookups in birthweight-related traits using data from the UK Biobank (see **Methods**).

185

We observed associations for rare LoF variants in *IGF1R* and *PAPPA2*, both of which are known regulators of insulin-like growth factor (IGF) regulation and bioactivity <sup>11–15</sup>, with adult circulating IGF-1 levels, adult height and childhood height and body size (**Supplementary Table 9**). The *INHBE, NRK, NOS3* and *NYNRIN* genes were also associated with adult height. In all of these genes, apart from *INHBE*, carrying a rare LoF variant was associated with directionally concordant effects on birth weight and adult height, i.e. higher birth weight and higher adult height or vice versa.

193

Furthermore, we observed associations between variants in *ADAMTS8* and *NOS3* and adult blood pressure (**Supplementary Table 9**). For both of these genes, rare LoF variants were associated with lower birth weight and higher blood pressure.

197

Finally, several of the birth weight associated genes were also associated with measures of adiposity in adulthood, including waist-hip ratio (WHR) adjusted for BMI, and body fat percentage for rare LoF variants in *ACVR1C*, *INHBE* and *PPARG* (accordingly, **Supplementary Table 9**). These are further explored below.

#### ACVR1C, INHBE and favourable adiposity

ACVR1C (birth weight: beta<sub>fetal</sub>=0.330 SDs, p=1.4×10<sup>-6</sup>, N=200 carriers, Figure 3a) encodes 203 a type I receptor for the TGF-beta family of signalling molecules. It is predominantly 204 expressed in adipose tissue<sup>10</sup> and its primary function in metabolic regulation is to limit 205 catabolic activities and preserve energy<sup>16</sup>. Low-frequency heterozygous mutations in humans 206 have been linked to a favourable metabolic profile including lower WHR adjusted for BMI and 207 protection against T2D<sup>17,18</sup>. INHBE (beta<sub>fetal</sub>=0.218 SDs, p=3.5×10<sup>-9</sup>, N=687 carriers, Figure 208 3b) encodes the inhibin subunit beta E of activin E, a growth factor belonging to the 209 TGF-beta family. While this gene is predominantly expressed in the liver<sup>10</sup>, it does not appear 210 to be necessary for normal liver function<sup>19</sup>, but rather acts as a negative regulator of energy 211 storage in peripheral adipose tissue. Similarly to ACVR1C, a candidate receptor, 212 heterozygous LoF carriers exhibit lower WHR adjusted for BMI and a favourable body fat 213 distribution and metabolic profile <sup>20,21</sup>. However, recent mouse studies <sup>22,23</sup> showed that 214 complete ablation of INHBE or ACVR1C leads to uncontrolled and pathological levels of 215 lipolysis (see Discussion). We found that rare LoF variants in ACVR1C and INHBE are 216 associated with increased birth weight and decreased WHR, indicative of a metabolically 217 favourable adiposity pattern in adulthood (Supplementary Table 9). 218

219

Two genetics studies <sup>20,21</sup> showed that the association between rare LoF variants in *INHBE* and WHR is primarily due to a splice acceptor variant (12:57456093:G:C) that substantially reduces the expression of the gene, attributable to either a change in secretion and/or protein

stability. They also reported that the favourable adiposity effect of this gene is almost entirely attenuated in the absence of this variant (gene-burden  $p=2.01\times10^{-8}$  with splice variant, p=0.34 without<sup>21</sup>, which we also observe for WHR in our data (**Supplementary Table 10**). However, while this variant is also strongly associated with higher birth weight ( $p=5.4\times10^{-6}$ , **Figure 3b**), our observed birth weight association with *INHBE* does not fully attenuate in the absence of this variant (gene-burden  $p=4.6\times10^{-9}$  with splice variant,  $p=6.3\times10^{-5}$  without, **Supplementary Table 10**).





#### 231

MISSENSE + PTV variants in *INHBE* with MAF<0.1% - Fetal analysis

Figure 3 | Rare variant associations at INHBE and ACVR1C with fetal birth weight in 232 the UK Biobank. Fetal variant-level associations between ACVR1C (a). INHBE (b) and birth 233 weight. Included variants had a minor allele frequency (MAF) <0.1% and were annotated to 234 be damaging variants defined as high-confidence protein truncating variants (PTV) or 235 missense variants with a CADD score ≥25. Each variant is presented as an individual line 236 extending to its association p-value ( $-\log_{10}$ ) in the direction indicating the direction of effect on 237 birth weight in variant carriers. Dashed lines indicate PTVs and solid lines indicate missense 238 variants. The point size indicates the number of carriers of each variant (i.e. the allele count). 239

240

#### 241 *PPARG* in birth weight, adipogenesis, and placental formation

*PPARG* (birth weight: beta<sub>fetal</sub>=-1.416 SDs,  $p=1.2\times10^{-6}$ , N=11 carriers, **Figure 4b**) encodes the 242 peroxisome proliferator-activated receptor PPAR-gamma, which acts as a master regulator of 243 adipogenesis. Heterozygous LoF variants in humans have been linked to familial partial 244 lipodystrophy (FPLD) characterised by loss of subcutaneous fat from the extremities and 245 metabolic abnormalities such as insulin resistance and hypertriglyceridemia <sup>24–27</sup>. Individuals 246 with FPLD due to inherited heterozygous variants have also been shown to have low 247 birthweight for their gestational age, when in the absence of maternal diabetes, hypertension 248 or hypertriglyceridemia (e.g. when the PPARG variants are paternally inherited)<sup>28</sup>. In addition 249 to being highly expressed in adipocytes, PPARG is also highly expressed in trophoblasts in 250 both rodent and human placentas<sup>29</sup> where it appears to play an important role in placental 251 formation and angiogenesis by regulating the expression of proangiogenic factors such as 252 proliferin (Prl2c2) and vascular endothelial growth factor (VEGF)<sup>30</sup>. Its depletion results in 253 embryonic lethality in mice due to placental dysfunction <sup>31,32</sup>, while PPARy agonist activity was 254 reduced in the blood and placentas of patients with severe preeclampsia, compared to those 255 with normal pregnancy<sup>33</sup>. 256

257

To distinguish if our observed birth weight association could be primarily due to PPARG's 258 function in fetal insulin resistance or placental function, we characterised rare variants in 259 PPARG using Missense InTerpretation by Experimental Response (MITER) score data<sup>34</sup>, as 260 the gold-standard indicator of lipodystrophy-causing PPARG missense variants. Although 261 MITER scores are not available for PTV variants, for which we observed the strongest birth 262 weight association, we note that 8 out of our included 9 PTV variants are classified as 263 pathogenic based on ACGS<sup>35</sup>. Missense variants with a lipodystrophy-level MITER score 264  $(\leq -2)$  were collectively associated with a decrease in adult body fat percentage of similar 265 magnitude to other prediction-based missense variant collapsing masks (p=9.70×10<sup>-5</sup>, Figure 266 4a, Supplementary Table 11). We found only weak evidence of an association between the 267 MITER score variants and birth weight (p=0.06), although the effect estimate on birth weight 268 was not significantly different from the other missense masks (Figure 4a, Supplementary 269 Table 11). There was also no discernible correlation pattern between PPARG variant effect 270 estimates on birth weight, body fat percentage and their corresponding MITER scores 271 (Pearson correlations were, R<sub>BW-MITER</sub>=0.026, R<sub>BF%-MITER</sub>=0.187, R<sub>BF%-BW</sub>=0.101, **Figure 4c**). 272 Taken together, our results suggest that the effects of rare PPARG PTVs on birth weight 273 could be due to altered placentation, as well as the established role in adipogenesis. 274

- 275
- 276



277

Figure 4 | Associations with rare LoF variants in PPARG. (a) Different (fetal) variant 278 collapsing masks and their associations with birth weight (top) and adult body fat percentage 279 (bottom). (b) The genomic location and associations with birth weight for all gualifying fetal 280 high confidence PTVs within PPARG, in the discovery analysis. (c) Scatterplot of association 281 P-values for birth weight (fetal variants) and body fat percentage, for all rare missense 282 variants in PPARG annotated with a MITER score and found in the UK Biobank population. 283 Marker colour indicates the variants MITER score, with scores ≤-2 indicating 284 lipodystrophy-level MITER scores. Relevant data is included in Supplementary Table 11. 285

286

As with PPARG, the ADAMTS8, NRK and NOS3 genes have also been implicated in 287 placental function. Specifically, ADAMTS8 shows strong placental expression in the early 288 stages of gestation and has been implicated in endometrium decidualization and trophoblast 289 invasion <sup>36–39</sup>. NRK encodes a serine/threonine kinase of the germinal centre kinase family 290 291 and is expressed in skeletal muscle during development as well as the placenta, specifically the spongiotrophoblast layer, a fetus-derived region of the placenta <sup>40-42</sup>. Nrk-deficient mouse 292 fetuses display enlarged placentas, a likely result of enhanced trophoblast proliferation due to 293 upregulation of AKT phosphorylation<sup>43</sup>, as well as a higher birth weight and delayed delivery 294 through yet unknown mechanisms<sup>42</sup>. Finally, common variants in NOS3 have been previously 295 associated with the risk of developing preeclampsia<sup>44</sup>, although no association was found at 296 this locus in a large-scale preeclampsia GWAS<sup>45</sup>. 297

# Comparison of burden test results with birth weight effects of pathogenic *GCK* variants

300 To investigate the sensitivity of our ExWAS approach to detect known rare variant effects on birth weight, we focused on the GCK gene. In the UK, pathogenic variants in GCK are the 301 second most common cause of monogenic diabetes, and have established effects on fetal 302 growth <sup>4,46</sup>. Mothers with pathogenic *GCK* variants have a stably raised fasting glucose level, 303 which results in greater glucose availability to the fetus, and increased birth weight due to 304 fetal insulin secretion, which is raised in response to higher maternal and consequently fetal 305 glucose. Conversely, fetal growth is reduced in babies who carry pathogenic GCK variants 306 due to their reduced insulin secretion. These birth weight effects are masked if both mother 307 and fetus carry the same mutation<sup>4</sup>. We annotated and combined pathogenic variants in GCK 308 using clinical guidelines<sup>35</sup> and observed evidence of both fetal and maternal genetic 309 associations with birth weight in the expected directions (beta<sub>fetal</sub>=-0.311 SDs, p=0.002, N=86 310 carriers; beta<sub>maternal</sub>=0.430 SDs, p=0.001, N=53 carriers; Supplementary Figure 8; 311 Supplementary Table 12). In comparison, our gene burden associations with rare predicted 312 LoF variants in GCK were more modest but in the expected directions (Supplementary 313 Figure 8; Supplementary Table 12). We found 63 of the known pathogenic GCK variants 314 present in the UK Biobank WES dataset. Out of 16 variants in the PTV mask, 14 were 315 annotated as pathogenic and of 55 variants in the Missense + PTV mask, 33 were annotated 316 317 as pathogenic. The remaining pathogenic variants were annotated as non-deleterious and were not included in the masks. 318

#### 319 Discussion

In this study, we used whole exome sequencing data from the UK Biobank cohort to 320 understand the influence of rare genetic variants on human birth weight. We aimed to identify 321 genes harbouring rare variants that impact birth weight when carried by either the fetus or the 322 mother. We identified a total of 8 genes with rare fetal LoF variant effects on birth weight, two 323 of which, IGF1R and NOS3 showed some evidence of maternal effects. We identified one 324 additional maternal effect gene, ADAMTS8. Findings were largely consistent in an 325 independent cohort of Icelandic genomes, and four of the identified genes harboured 326 independent GWAS lead SNPs in the largest and most recent birth weight GWAS 327 meta-analysis, providing additional confirmation that the genes identified in this study are 328 involved in birth weight regulation. 329

330

Among the genes associated with birth weight, several have well-established links with fetal 331 growth. IGF1R and PAPPA2 encode key components of IGF bioavailability and signalling. 332 IGF1R is a transmembrane receptor tyrosine kinase activated by IGF1 (and also IGF2 and 333 insulin), which mediates anabolic effects. Rare human homozygous, heterozygous or 334 compound heterozygous mutations in *IGF1R* cause intrauterine growth restriction, reduced 335 postnatal growth, short stature and microcephaly<sup>47</sup>. PAPPA2 encodes a metalloproteinase 336 that regulates the bioavailability of IGFs. Rare homozygous mutations in PAPPA2 are 337 reported to cause severe short stature but with unclear effects on birth weight (reduced in 4 338

of 6 affected children)<sup>48</sup>, while the protein originates primarily from trophoblasts in the early placenta<sup>49,50</sup>. Our findings demonstrate that rare, damaging variants in *IGF1R* and *PAPPA2* contribute to population variation in birth weight, as well as in childhood and adult height.

342

Consistent with the fetal insulin hypothesis<sup>51</sup>, the association between the rare, damaging 343 fetal variants in IGF1R and greater type 2 diabetes risk provides a potential mechanistic 344 insight into the well-documented link between this later-life disease and lower birth weight. 345 *IGF1R* is central to the development of several key tissues for glucose metabolism, including 346 pancreatic islets, adipose tissue and skeletal muscle<sup>52</sup>, and in addition, loss of IGF1R 347 function may lead to compensatory increases in growth hormone levels, which are 348 associated with insulin resistance<sup>53</sup>. The mechanism underlying the association we observed 349 between maternal rare, damaging IGF1R variants and lower offspring birth weight after 350 adjustment for fetal genotype is, however, less clear because we would expect such variants 351 to increase birth weight if they result in higher maternal insulin resistance with concomitant 352 higher glucose availability. However, there are some reported cases of heterozygous IGF1R 353 mutations leading to hypoglycemia<sup>54</sup>. We recommend that this result is confirmed in 354 well-powered samples of mother-child pairs before potential mechanisms are investigated. 355

PPARG, INHBE, and ACVR1C displayed fetal effects on birthweight and are involved in 357 adipose tissue differentiation and regulation. Recent genetics studies implicated rare LoF 358 variants in INHBE in adult favourable adiposity traits, i.e. lower WHR adjusted for BMI <sup>20,21</sup>. 359 They also highlighted a splice variant (12:57456093:G:C) which affects either protein 360 secretion or stability, as underpinning the favourable adiposity association with this gene. We 361 found that the birth weight association with INHBE largely remains, even in the absence of 362 this splice variant. This could indicate that some variants within INHBE may exert a role in 363 early (in utero) adipogenesis, while others may do so throughout the life course, but further 364 studies need to confirm this hypothesis. 365

366

356

Our identification of rare LoF variants in two genes, ACVR1C and INHBE, that have fetal 367 associations with higher birth weight and also a more metabolically favourable body fat 368 distribution in adulthood is in line with recent findings that common genetic variants in the 369 fetus, which predispose to higher metabolically favourable adiposity in adulthood, are also 370 associated with higher birth weight. Variants with greater effects on adiposity have greater 371 effects on birth weight<sup>55</sup> and we therefore hypothesise that the birth weight effects of 372 ACVR1C and INHBE are due primarily to fetal fat accretion rather than effects on lean mass. 373 A fetal genetic predisposition to greater birth weight and later favourable body fat distribution 374 may underlie epidemiological associations between greater skinfold thickness at birth and 375 favourable metabolic outcomes in early childhood, especially when controlling for exposure to 376 maternal glucose levels in utero<sup>56</sup>. Further studies should assess the contributions of rare 377 variation in ACVR1C and INHBE to the fat and lean mass components of birth weight. 378

379

More generally, the effects of loss of INHBE on Alk7 (ACVR1C) signalling on metabolic health appear to be complex and dose-dependent. Humans haploinsufficient for either of these genes have a healthy metabolic profile and reduced risk of cardiometabolic disease

accompanied by a favourable distribution of body fat. However, it has been shown that the 383 total absence of either INHBE or ACVR1C from conception results in uncontrolled adipocyte 384 lipolysis, ectopic fat distribution and insulin resistance, at least in mice <sup>22,23</sup>. This discrepancy 385 may be explained by the fact that Alk7 signalling in adipose cells suppresses the expression 386 of both PPARy and key molecular elements of the lipolytic machinery. We suggest that at 387 modest levels of INHBE/Alk7 deficiency, such as occurs when only one functional allele is 388 present, the effect on PPARy is dominant and carriers of such mutations develop more 389 390 subcutaneous adipocytes as a result of the enhanced PPARG tone during development. Ultimately, this is metabolically beneficial as it will tend to protect the individual from any 391 effects of any caloric overload in postnatal life. However, in the total absence of INHBE/Alk7 392 the effect on lipolysis becomes dominant with consequent build-up of ectopic fat and insulin 393 resistance. While it is not entirely clear why subcutaneous, rather than visceral adipocytes 394 would be favoured by PPARy activity, it is worthy of note that the administration of drugs 395 activating PPARy preferentially promotes subcutaneous fat deposition<sup>57</sup>. 396

397

Heterozygous LoF in PPARG has previously been linked to familial partial lipodystrophy, 398 characterised by the loss of subcutaneous fat from the extremities and metabolic 399 abnormalities such as insulin resistance and hypertriglyceridemia <sup>24-27</sup>. However, *PPARG* has 400 also been linked to placental development and angiogenesis<sup>30</sup>. Here, we saw a poor 401 correlation between the variants' lipodystrophy-causing potential and effect on birth weight, 402 suggesting the birth weight effect could be driven by another mechanism. Given the role of 403 PPARG in placental development, it is possible that PPARG LoF variants act via the 404 placenta to exert an effect on birth weight. Our results are consistent with recent observations 405 of a high rate of small-for-gestational-age birth weights in patients who had familial partial 406 lipodystrophy due to inherited PPARG mutations and who were not exposed to maternal 407 diabetes in utero<sup>28</sup>. PPARG mutation carriers were also more likely to be born preterm. 408 regardless of maternal diabetes status, which further supports the role of fetal PPARG in 409 placental development. Data on gestational duration was not available for the UK Biobank 410 participants, and it is possible that shorter gestation in rare PPARG variant carriers 411 contributed to the associations we observed with birth weight. We note that the common fetal 412 variant rs1801282 in PPARG, which is associated with type 2 diabetes risk in adulthood<sup>58</sup> via 413 a fat distribution-mediated form of insulin resistance<sup>59</sup>, is weakly associated with lower birth 414 weight (p=0.0259)<sup>5</sup> and was not associated with gestational duration in a fetal GWAS of 415 gestational duration in 84,689 individuals (p=0.487)<sup>60</sup>. Our observed associations between 416 birthweight and ADAMTS8, NRK and NOS3 are also likely driven by placental mechanisms, 417 given the known roles of these genes <sup>36-44</sup>. The potential mechanism underlying the association 418 between birth weight and our other identified gene, NYNRIN, requires further study. 419

420

Our study has several strengths, including a large discovery sample, an independent replication sample, support from common variant associations proximal to five of the genes, and approximate adjustment for correlation between maternal and fetal genotype. However, there are limitations. The sample size available for replication was limited, and although we observed strong evidence for consistent effect estimates, we recommend confirmation in larger datasets as they become available, along with proper conditional analyses in

sufficiently-powered samples of mother-child pairs. The approximate adjustment for the 427 correlation between maternal and fetal genotype used here is based on the strong 428 assumption that all variants with a given annotation have equal effects on birth weight<sup>5</sup>, which 429 may not be the case. We also acknowledge the limited diversity of our samples. Studies of 430 rare variants in well-powered samples of diverse ancestries are a priority for future research. 431 While our study was underpowered to detect very rare pathogenic variants that have known 432 birth weight effects<sup>2</sup>, our sensitivity analysis of GCK showed that the known maternal and 433 434 fetal associations were detectable by our method, despite the inevitable lower sensitivity and specificity of the exome-wide approach, and despite the lack of adjustment for opposing 435 436 effects of maternal and fetal genotypes.

437

Overall, this study advances our understanding of the fetal and maternal genetic underpinnings of birth weight, providing strong evidence for causal genes and insights into biological pathways which are important targets for future research aiming to understand fetal growth and its links with long-term health.

# 442 Acknowledgements

This research has been conducted using the UK Biobank Resource under Application
Numbers 9905 and 7036. UK Biobank data has approval from the North West Multi-centre
Research Ethics Committee (MREC) as a Research Tissue Bank (RTB).

Use of the Icelandic data was approved by the National Bioethics Committee (VSN-15-169).
All genotyped participants signed a written informed consent allowing the use of their
samples and data in projects at deCODE genetics approved by the NBC. Data were
anonymized and encrypted by a third-party system, approved and monitored by the Icelandic
Data Protection Authority<sup>61</sup>.

B.E.M.L., R.N.B. and R.M.F. were supported by a Wellcome Senior Research Fellowship 451 (WT220390). This research was funded in part by the Wellcome Trust (WT220390). R.M.F. is 452 also supported by a grant from the Eunice Kennedy Shriver National Institute Of Child Health 453 & Human Development of the National Institutes of Health under Award Number 454 R01HD101669. K.A.K., L.R.K., E.J.G., Y.Z., F.R.D., K.K.O. and J.R.B.P. are supported by the 455 Medical Research Council (MC UU 00006/2). This study was supported by the National 456 Institute for Health and Care Research (NIHR) Exeter Biomedical Research Centre and the 457 NIHR Cambridge Comprehensive Biomedical Research Centre. The views expressed are 458 those of the authors and not necessarily those of the NIHR or the Department of Health and 459 Social Care. For the purpose of open access, the authors have applied a CC BY public 460 copyright licence to any Author Accepted Manuscript version arising from this submission. 461

#### 462

# 463 Author contributions

K.A.K., B.E.M.L., L.R.K., K.K.O., R.N.B., J.R.B.P., and R.M.F. analysed and interpreted the
original data and wrote the manuscript. V.S., V.T., T.O., G.T., and K.S. contributed the
Icelandic replication data. L.S., K.A.P., G.H., E.J.G., A.R.W., Y.Z., F.R.D., S.E.O., A.T.H., and
S.O. contributed to data analysis and/or interpretation. All authors revised, critically reviewed
and approved the manuscript.

469

# 470 Competing interests

J.R.B.P. and E.J.G. are employees/shareholders of Insmed. J.R.B.P. also receives research
funding from GSK. Y.Z. is a UK University worker at GSK. S.O. has undertaken remunerated
consultancy work for Pfizer, Third Rock Ventures, AstraZeneca, NorthSea Therapeutics and
Courage Therapeutics. V.S., V.T., T.O., G.T., and K.S. are employees of deCODE genetics, a
subsidiary of Amgen.

476

# 477 Code availability

Code for WES data processing and association testing is available on GitHub
 (<u>https://github.com/mrcepid-rap/mrcepid-runassociationtesting</u>). No custom code was
 developed for this study.

#### <sup>481</sup> Data availability

- 482 UK Biobank data are available on application via
- 483 <u>https://www.ukbiobank.ac.uk/enable-your-research/register</u>.

# 484 Materials and methods

#### Exome wide association analyses in the UK Biobank

Analyses of the UK Biobank data were performed on the UK Biobank Research Analysis 486 Platform (RAP: https://ukbiobank.dnanexus.com/). Birth weight was derived in the 453,505 487 UK Biobank participants with genetically defined European ancestry, as follows. Own birth 488 weight (fetal genotype analysis) was derived using self-reported data (field 20022), while birth 489 weight of the first child in UK Biobank women (maternal genotype analysis) was taken from 490 hospital records and self-reports (fields 41284 and 2744). Data from each field were 491 converted to kg (if in another unit) and if both were available, hospital records were 492 preferentially retained for maximum accuracy. For both phenotypes, repeated responses 493 across the assessment centre visits were combined by calculating average values. 494 Individuals from multiple births (field 1777), who reported substantially different values 495 between visits (>1kg difference), or extreme birth weight values (<1 or  $\geq$ 7kg) were excluded 496 497 from downstream analyses. After these exclusions, fetal birth weight data was available for 252,329 individuals (234,675 with exome and covariate data) and maternal birth weight data 498 was available for the first child of 195,653 women (181,883 with exome and covariate data). 499 500

We conducted gene burden tests for both fetal and maternal birth weight, by combining 501 effects of all rare (MAF < 0.1%) variants with predicted deleterious functional consequences 502 across all protein-coding genes, as described in detail in Gardner et al.53. Briefly, we gueried 503 population-level VCF files with data for 454,787 individuals provided from the UK Biobank 504 study. Using bcftools<sup>62</sup> multi-allelic variants were split and left-normalised, and all variants 505 filtered using a missingness based approach. SNV genotypes with depth <7 and genotype 506 quality <20 or InDel genotypes with a depth <10 and genotype guality <20 were set to 507 missing. We also tested for an expected reference and alternate allele balance of 50% for 508 heterozygous SNVs using a binomial test; SNV genotypes with a binomial test p. value 509 ≤1×10<sup>-3</sup> were set to missing. Following genotype filtering, variants with >50% missing 510 genotypes were excluded from further analysis. Variants were then annotated with the 511 ENSEMBL Variant Effect Predictor (VEP<sup>63</sup>, v104) with the 'everything' flag and the LOFTEE 512 plugin<sup>64</sup>. For each variant we prioritised a single MANE (v0.97) or VEP canonical ENSEMBL 513 transcript and most damaging consequence as defined by VEP defaults. For the purposes of 514 defining Protein Truncating Variants (PTVs), we grouped high-confidence (as defined by 515 LOFTEE) stop gained, splice donor/acceptor, and frameshift consequences. To define 516 'high-confidence' PTVs, we used the LOFTEE algorithm<sup>64</sup>. All variants were subsequently 517 annotated using CADD (v1.6, <sup>65</sup>). We then assessed the association between rare variant 518 burden and birth weight, using BOLT-LMM (v2.3.5, <sup>66</sup>) and a set of dummy genotypes 519 representing per-gene carrier status, under two overlapping variant collapsing masks; i) 520

high-confidence protein truncating variants (denoted PTV) and ii) High-confidence PTVs plus missense variants with CADD scores  $\geq$ 25 (denoted Missense + PTV). All analyses were controlled for age, age<sup>2</sup>, the first ten genetic ancestry principal components as calculated in Bycroft *et al.*<sup>67</sup>, WES batch, and sex when running sex-combined analyses. We excluded genes with <10 carriers of variants per mask.

526

This led to testing 16,735 genes with gualifying Missense + PTV variants and 13,684 with 527 PTVs for fetal birth weight, and 17,745 with Missense + PTV variants and 13,968 with PTVs 528 for maternal birth weight. The exome-wide significance thresholds were thus set to 529  $p=1.64 \times 10^{-6}$ (0.05/(16735+13684)) $p=1.58\times10^{-6}$ 530 for fetal birth weight and (0.05/(17745+13968)) for maternal birth weight. 531

532 Confirmatory gene burden analyses

To replicate the findings from the above analysis and account for potential bias arising from only using one discovery approach, a second team independently derived the birth weight phenotypes for the maternal and fetal genetic analyses and conducted additional burden association analyses, specifically for the significantly associated birth weight genes.

Own birth weight (fetal genotype analysis) was derived using self-reported data (field 20022), 537 excluding individuals who were part of a multiple birth (field 1777). Offspring birth weight 538 (maternal genotype analysis) was derived from self reported weight of first child (field 2744). 539 Where individuals reported their birth weight at more than one assessment centre visit, 540 reported birth weights were averaged unless the weights differed by  $\geq 1$  kg, in which case 541 they were excluded. Own and offspring birth weight were available in 269,921 (232,876 with 542 543 exome and covariate data) and 216,798 (152,585 with exome and covariate data) individuals respectively. 544

545

Multiallelic variants were similarly split and left-normalised. Variants flagged for exclusion by 546 UK Biobank were removed, and remaining variants were annotated with their functional 547 consequence in canonical transcripts using the Ensembl Variant Effect Predictor and the 548 549 CADD and LOFTEE plugins (https://github.com/konradjk/loftee). Association testing was performed using REGENIE (v3.1.3, 68), and variants were grouped according to two 550 collapsing masks; i) loss of function variants defined by LOFTEE as high confidence 551 (denoted PTV) and ii) LoF plus missense SNVs or inframe insertions or deletions with CADD 552 scores ≥25 (denoted Missense + PTV). All analyses were controlled for maternal age at first 553 birth (field 3872) or year of birth, sex (for fetal birth weight), assessment centre, WES 554 sequencing batch, and the first ten principal components. 555

556

Exome-wide significantly associated genes from the above BOLT-LMM analysis were queriedin the REGENIE results.

#### 559 Follow-up analyses of identified genes

To distinguish between fetal genotyping-acting ('fetal-acting') and maternal genotype-acting ('maternal-acting') effects at each birth weight-associated gene, we applied a weighted linear model (WLM) to the burden test results. WLM estimates associations of fetal genotype conditional on maternal genotype, and vice versa, without the need for data from mother-child pairs. The WLM approach has been described previously<sup>5</sup>.

565

To investigate potential sexual dimorphism, we performed sex-stratified burden tests using generalised linear models in the discovery sample and for the most strongly associated mask-gene combination. Sex-stratified effect estimates for each gene were compared using two-sample T-tests. Associations were deemed dimorphic if the *p*-value for the T-test was <0.05.

571

572 Where described, further missense variant collapsing masks and leave-one out analyses 573 were tested using BOLT-LMM or linear models in the same individuals and birth weight 574 outcomes as the discovery analyses. Such masks were defined using a combination of 575 CADD<sup>65</sup> and REVEL<sup>69</sup>.

576

577 Conditional analyses where the effect of the identified rare exome variant collapsing masks was conditioned on the genotype at common birth weight GWAS signals were also tested 578 using linear models in the same individuals and birth weight outcomes as the discovery 579 analyses. Genotypes at GWAS signals (as identified in <sup>6</sup>) were extracted in this discovery 580 sample using plink (v1.90b6.18, 70). Birthweight outcomes were regressed against the 581 covariates used in discovery analyses and the concurrent effects of exome variant carriage 582 and GWAS signal genotype were tested against the residual birth weight variance. A change 583 in effect estimate of more than 10% was considered to show significant attenuation in the 584 presence of the GWAS variants. 585

#### 586 Related trait PheWAS

587 For all identified exome associations to the two birth weight traits, we performed small-scale 588 PheWAS on a few predefined relevant phenotypes.

589

For BOLT-LMM analyses, phenotypic outcomes were defined as follows. BMI raw values 590 591 were used from field 21001. Body fat % was extracted using data from field 23099. Data from subsequent visits were used, if missing for a given instance. Comparative height at age 10 592 was recoded to have individuals who in field 1697 reported being 'Shorter' as 0, 'About 593 average' as 1, and 'Taller' as 2. Individuals who reported 'Do not know' or 'Prefer not to 594 answer' were set to 'NA'. Following variable recoding, this phenotype was run as a 595 continuous trait. Comparative size at age 10 was defined as above using data from field 596 1687. Systolic and diastolic blood pressure was derived using data from fields 4079 and 597 4080, accordingly. For each, the average blood pressure at each assessment visit was 598 calculated over the two available measurements and data from subsequent visits were used, 599 if missing for a given instance. Individuals indicating the use of blood pressure medications in 600

fields 6153 and 6177 were adjusted for in the association models. Height raw values were 601 used from field 50. IGF-1 levels were derived using data from field 30770, with exclusion of 602 individuals >5 standard deviations from the mean. T2D was derived as described in <sup>53</sup> and 603 using data from fields 4041, 10844, 2443, 6177, 6153, 20002, 20003, 41202, 41204, 604 40001and 40002. WHR adjusted for BMI; WHR was calculated using data from field 48 and 605 49. >4 standard deviations from the mean excluded following initial calculation and prior to 606 adjusting with BMI (field 21001). Paired BMI and WHR data from subsequent visits were 607 used, if missing for a given instance. 608

609

For REGENIE analyses, phenotypic outcomes are as follows: BMI was taken from the 610 baseline value for field 21001 and residualised on age at assessment (field 21003), genetic 611 sex (field 22001), assessment centre (field 54) and PCs 1-5. Blood pressure measurements 612 were taken from the automated readings for diastolic blood pressure (field 4079) and systolic 613 blood pressure (field 4080). Where two blood pressure readings were available, the average 614 between the two was taken, excluding individuals where the measurements differed by >4.56 615 SD. Individuals with a blood pressure >4.56 SD away from the mean were excluded. Blood 616 pressure medication was accounted for by adding 10 and 15 mmHg to diastolic and systolic 617 blood pressure, respectively. Height raw values were taken from baseline values for field 50, 618 where people whose height was 100 cm and sitting height (field 20015) was 20 cm, were 619 removed. Raw IGF-1 values were used from field 30770. Size at age 10 was based on a 620 continuous simulation of childhood BMI. The simulation converted the categorical variables 621 622 'thinner', 'the same size' or 'plumper' in field 1687 to a continuous distribution based on the number of individuals selecting each category. The full methods for the simulation have 623 previously been reported<sup>71</sup>. WHR was calculated using waist circumference (field 48) and hip 624 625 circumference (field 49). If a follow-up visit was recorded, the WHR was taken from the follow-up data. Otherwise, it was taken from the first recorded WHR measurement. 626

627

The multiple testing threshold was set at p<0.005, after correcting for the above 10 queried phenotypes.

630 GWAS associations at identified loci

GWAS signals for fetal and maternal birth weight were accessed from Juliusdottir *et al.*<sup>6</sup>. These signals were lifted back to GRCh37 annotated with all proximal genes, defined as those within 500kb up- or downstream of the genes start or end sites, using the NCBI RefSeq gene map for GRCh37 (via <u>http://hgdownload.soe.ucsc.edu/goldenPath/hg19/database/</u>). For signals proximal to the exome-associated genes we assessed whether the exome-associated gene was the closest gene to the GWAS signal. These signals were also queried using eQTL data from the GTEx study (V8, <sup>10</sup>) and plotted using LocusZoom<sup>72</sup>.

638

We performed gene-centric biological pathway enrichment analysis using g:Profiler (via the R client "gprofiler2"<sup>73</sup>, v0.2.1, accessed on 23/11/2023). Pathway enrichment analyses were performed using the genes calculated to be the closest per signal to the GWAS signals from Juliusdottir *et al.*<sup>6</sup>. Pathways with a Bonferroni corrected *p*-value<0.05 were considered significantly enriched in the birth weight GWAS.

#### 644

We also examined all genes within 300 kb of the previously published birth weight loci from Juliusdottir *et al.*<sup>6</sup>. For this restricted set of loci previously shown to have common genetic associations with birth weight, we applied a Benjamini-Hochberg procedure to identify genes with evidence of association.

649 Replication of exome associations in deCODE

#### 650 Data preparation

The genome of the Icelandic population was characterised by whole-genome sequencing (WGS) of 63,460 Icelanders using Illumina standard TruSeq methodology to a mean depth of 35x (SD 8x) with subsequent long-range phasing<sup>74</sup>, and imputing the information into 173,025 individuals chip-genotyped employing multiple Illumina platforms<sup>75</sup>. Variant calling was performed using GraphTyper<sup>76</sup> (v2.6) and chip data was phased using SHAPEIT4<sup>77</sup>.

We used Variant Effect Predictor (VEP<sup>63</sup>) to attribute predicted consequences to the variants sequenced in each dataset. We classified as high-impact variants those predicted as start-lost, stop-gain, stop-lost, splice donor, splice acceptor or frameshift, collectively called loss-of-function (LOF) variants. Variants of moderate impact are those classified as missense, splice-region and in-frame-indels.

Information on birthweight comes from the Icelandic birth register and Primary Health Care
 Clinics of the Capital area. Individual's fetal birth weight was available in up to 36,578
 genotyped and 11,184 WGS participants, while maternal birth weight was available in 45,622
 genotyped and 17,177 WGS participants.

#### 665 Gene burden associations

We defined different models to group together various types of variant: (i) only LOF variants, filtered with LOFTEE<sup>64</sup>; (ii) LOF and MIS (as described on Variant annotation), when predicted deleterious by CADD<sup>65</sup> score  $\geq$  25. In all models, we used MAF < 0.1% to select variants for analyses.

Quantitative traits were analysed using a linear mixed model implemented in BOLT-LMM<sup>66</sup>. To 670 estimate the guality of the sequence variants across the entire set we regressed the 671 alternative allele counts (AD) on the depth (DP) conditioned on the genotypes (GT) reported 672 by GraphTyper<sup>78</sup>. For a well behaving sequence variant, the mean alternative allele count for 673 a homozygous reference genotype should be 0, for a heterozygous genotype it should be 674 DP/2 and for homozygous alternative genotype it should be DP. Under the assumption of no 675 sequencing or genotyping error, the expected value of AD should be DP conditioned on the 676 genotype, in other words an identity line (slope 1 and intercept 0). Deviations from the identity 677 line indicate that the sequence variant is spurious or somatic. We filter variants with slope 678 679 less than 0.5. Additionally, GraphTyper employs a logistic regression model that assigns each variant a score (AAscore) predicting the probability that it is a true positive. We used only 680 variants that have a AAscore > 0.8. 681

#### 682 Analysis of birth weight associations with pathogenic *GCK* mutations

We used a similar procedure to that used to define pathogenic variants in GCK in a recent 683 paper<sup>79</sup>. We reviewed all heterozygous missense/PTV variants in UK Biobank participants 684 with whole exome sequencing that were observed at minor allele frequency (MAF) <0.001. 685 We included variants in the analysis if missense/PTV variants were classified as pathogenic 686 or likely pathogenic based on ACMG/AMP guidelines by clinical scientists at Exeter 687 Molecular Genetic laboratory as part of routine clinical diagnostic care (i.e. previously seen in 688 the MODY probands)<sup>35</sup> and were ultra-rare in the population (maximum allele count of 2 in 689 gnomADv2.1, MAF <1.4x10<sup>-5</sup>). We manually reviewed sequence read data for all the 690 pathogenic variants (missense and PTVs) in Integrative Genomics Viewer (IGV) to remove 691 692 false-positive variants. We used linear regression to assess the difference in birth weight associated with being a carrier (separate maternal and fetal analyses) and adjusted for 693 genotype, sex, mother's diabetes status, batch, year of birth, centre and principal 694 components in the fetal analysis and genotype, batch, age at first birth, centre and principal 695 components in the maternal birth weight analysis. We then compared the estimated effects 696 and 95% confidence intervals for the pathogenic variants with those obtained from our PTV 697 and PTV+missense masks in the REGENIE analyses. 698

# 699 References

- 700
- 1. Barker, D. J. et al. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and
- hyperlipidaemia (syndrome X): relation to reduced fetal growth. *Diabetologia* **36**, 62–67
- 703 (1993).
- 2. Hughes, A. E., Hattersley, A. T., Flanagan, S. E. & Freathy, R. M. Two decades since the
- fetal insulin hypothesis: what have we learned from genetics? *Diabetologia* 64, 717–726
- 706 (2021).
- 3. Hughes, A. E. et al. Monogenic disease analysis establishes that fetal insulin accounts
- for half of human fetal growth. J. Clin. Invest. 133, e165402 (2023).
- 4. Hattersley, A. T. et al. Mutations in the glucokinase gene of the fetus result in reduced
- <sup>710</sup> birth weight. *Nat. Genet.* **19**, 268–270 (1998).
- 5. Warrington, N. M. *et al.* Maternal and fetal genetic effects on birth weight and their
- relevance to cardio-metabolic risk factors. *Nat. Genet.* **51**, 804–814 (2019).
- 6. Juliusdottir, T. et al. Distinction between the effects of parental and fetal genomes on
- <sup>714</sup> fetal growth. *Nat. Genet.* **53**, 1135–1142 (2021).
- 715 7. Hughes, A. E. *et al.* Fetal Genotype and Maternal Glucose Have Independent and
- Additive Effects on Birth Weight. *Diabetes* **67**, 1024–1029 (2018).
- 8. Aragam, K. G. et al. Discovery and systematic characterization of risk variants and
- genes for coronary artery disease in over a million participants. *Nat. Genet.* **54**, 1803–1815
- 719 (2022).
- 9. Mountjoy, E. *et al.* An open approach to systematically prioritize causal variants and
- genes at all published human GWAS trait-associated loci. *Nat. Genet.* **53**, 1527–1533 (2021).
- 10. Lonsdale, J. *et al.* The genotype-tissue expression (GTEx) project. *Nat. Genet.* **45**, 580
- 723 (2013).
- 11. Sferruzzi-Perri, A. N., Sandovici, I., Constancia, M. & Fowden, A. L. Placental phenotype

and the insulin-like growth factors: resource allocation to fetal growth. J. Physiol. 595,

726 5057–5093 (2017).

- 12. Conover, C. A. et al. Metalloproteinase pregnancy-associated plasma protein A is a
- ritical growth regulatory factor during fetal development. *Dev. Camb. Engl.* **131**, 1187–1194
- 729 (2004).
- 13. Bøtkjær, J. A., Noer, P. R., Oxvig, C. & Yding Andersen, C. A common variant of the
- 731 pregnancy-associated plasma protein-A (PAPPA) gene encodes a protein with reduced
- proteolytic activity towards IGF-binding proteins. *Sci. Rep.* **9**, 13231 (2019).
- 14. Yan, X., Baxter, R. C. & Firth, S. M. Involvement of pregnancy-associated plasma
- protein-A2 in insulin-like growth factor (IGF) binding protein-5 proteolysis during pregnancy: a
- potential mechanism for increasing IGF bioavailability. J. Clin. Endocrinol. Metab. 95,
- 736 1412–1420 (2010).
- 15. Dauber, A. *et al.* Mutations in pregnancy-associated plasma protein A2 cause short
- stature due to low IGF-I availability. *EMBO Mol. Med.* **8**, 363–374 (2016).
- 16. Ibáñez, C. F. Regulation of metabolic homeostasis by the TGF-β superfamily receptor
- 740 ALK7. FEBS J. 289, 5776–5797 (2022).
- 17. Justice, A. E. *et al.* Protein-coding variants implicate novel genes related to lipid
- homeostasis contributing to body-fat distribution. *Nat. Genet.* 1 (2019).
- 18. Emdin, C. A. *et al.* DNA Sequence Variation in ACVR1C Encoding the Activin
- 744 Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2
- 745 Diabetes. *Diabetes* **68**, 226–234 (2019).
- 19. Lau, A. L., Kumar, T. R., Nishimori, K., Bonadio, J. & Matzuk, M. M. Activin betaC and
- <sup>747</sup> betaE genes are not essential for mouse liver growth, differentiation, and regeneration. *Mol.*
- 748 Cell. Biol. 20, 6127–6137 (2000).
- 20. Akbari, P. et al. Multiancestry exome sequencing reveals INHBE mutations associated
- vith favorable fat distribution and protection from diabetes. *Nat. Commun.* **13**, 4844 (2022).

- 751 21. Deaton, A. M. *et al.* Rare loss of function variants in the hepatokine gene INHBE protect
  752 from abdominal obesity. *Nat. Commun.* **13**, 4319 (2022).
- 22. Griffin, J. D. et al. Hepatic Activin E mediates liver-adipose inter-organ communication,
- <sup>754</sup> suppressing adipose lipolysis in response to elevated serum fatty acids. *Mol. Metab.* **78**,
- 755 101830 (2023).
- 23. Adam, R. C. *et al.* Activin E-ACVR1C cross talk controls energy storage via suppression
- <sup>757</sup> of adipose lipolysis in mice. *Proc. Natl. Acad. Sci. U. S. A.* **120**, e2309967120 (2023).
- 758 24. Agarwal, A. K. & Garg, A. A novel heterozygous mutation in peroxisome
- <sup>759</sup> proliferator-activated receptor-gamma gene in a patient with familial partial lipodystrophy. J.
- 760 Clin. Endocrinol. Metab. 87, 408–411 (2002).
- 761 25. Barroso, I. *et al.* Dominant negative mutations in human PPARgamma associated with
- resistance, diabetes mellitus and hypertension. *Nature* **402**, 880–883 (1999).
- 763 26. Hegele, R. A., Cao, H., Frankowski, C., Mathews, S. T. & Leff, T. PPARG F388L, a
- transactivation-deficient mutant, in familial partial lipodystrophy. *Diabetes* **51**, 3586–3590
- 765 (2002).
- 766 27. Savage, D. B. et al. Human metabolic syndrome resulting from dominant-negative
- <sup>767</sup> mutations in the nuclear receptor peroxisome proliferator-activated receptor-gamma.
- 768 Diabetes 52, 910–917 (2003).
- 28. Gosseaume, C. *et al.* Perinatal, metabolic, and reproductive features in PPARG-related
  lipodystrophy. *Eur. J. Endocrinol.* **188**, Ivad023 (2023).
- Placenta 28, 65–76 (2007).
  Placenta 28, 65–76 (2007).
- 30. Nadra, K. *et al.* PPARgamma in placental angiogenesis. *Endocrinology* **151**, 4969–4981
  (2010).
- 31. Barak, Y. *et al.* PPAR gamma is required for placental, cardiac, and adipose tissue
  development. *Mol. Cell* 4, 585–595 (1999).

24

- 32. Kubota, N. et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy
- and insulin resistance. *Mol. Cell* **4**, 597–609 (1999).
- 33. Waite, L. L., Louie, R. E. & Taylor, R. N. Circulating Activators of Peroxisome
- 780 Proliferator-Activated Receptors Are Reduced in Preeclamptic Pregnancy. J. Clin. Endocrinol.
- 781 *Metab.* **90**, 620–626 (2005).
- 782 34. Majithia, A. R. *et al.* Prospective functional classification of all possible missense
- variants in PPARG. *Nat. Genet.* **48**, 1570–1575 (2016).
- 35. Ellard, S. *et al.* ACGS Best Practice Guidelines for Variant Classification in Rare Disease
  2020. ACGS (2020).
- 36. Wen, J., Zhu, H. & Leung, P. C. K. Gonadal steroids regulate the expression of
- aggrecanases in human endometrial stromal cells in vitro. *J. Cell. Mol. Med.* **17**, 1325–1334
  (2013).
- 37. Namli Kalem, M., Kalem, Z., Bakirarar, B. & Demircan, K. Adamts 1, 4, 5, 8, and 9 in
  Early Pregnancies. *Fetal Pediatr. Pathol.* 36, 387–399 (2017).
- 38. Qu, H. & Khalil, R. A. Role of ADAM and ADAMTS disintegrin and metalloproteinases in
- normal pregnancy and preeclampsia. *Biochem. Pharmacol.* **206**, 115266 (2022).
- 39. Tatar, M., Uslu, S. & Öner, J. Expression of placental growth factor and a disintegrin and
- metalloprotease with a thrombospondin type motifs 1-4-8 during the three trimesters of rat
- pregnancy at the maternal-fetal interface. *Anat. Histol. Embryol.* **52**, 805–814 (2023).
- 40. Kanai-Azuma, M. et al. Nrk: a murine X-linked NIK (Nck-interacting kinase)-related
- kinase gene expressed in skeletal muscle. *Mech. Dev.* 89, 155–159 (1999).
- 41. Nakano, K., Yamauchi, J., Nakagawa, K., Itoh, H. & Kitamura, N. NESK, a member of
- the germinal center kinase family that activates the c-Jun N-terminal kinase pathway and is
- expressed during the late stages of embryogenesis. J. Biol. Chem. 275, 20533–20539
- 801 (2000).
- 42. Denda, K. et al. Nrk, an X-linked protein kinase in the germinal center kinase family, is

- required for placental development and fetoplacental induction of labor. J. Biol. Chem. 286,
- 804 28802–28810 (2011).
- 43. Morioka, Y., Nam, J.-M. & Ohashi, T. Nik-related kinase regulates trophoblast
- proliferation and placental development by modulating AKT phosphorylation. *PloS One* **12**,
- e0171503 (2017).
- 44. Zeng, F. *et al.* Associations between nitric oxide synthase 3 gene polymorphisms and
- preeclampsia risk: a meta-analysis. *Sci. Rep.* **6**, 23407 (2016).
- 45. Honigberg, M. C. et al. Polygenic prediction of preeclampsia and gestational
- hypertension. *Nat. Med.* **29**, 1540–1549 (2023).
- 46. Thanabalasingham, G. & Owen, K. R. Diagnosis and management of maturity onset
- diabetes of the young (MODY). *BMJ* **343**, d6044 (2011).
- 47. Murray, P. G. & Clayton, P. E. Disorders of Growth Hormone in Childhood. in *Endotext*
- (eds. Feingold, K. R. et al.) (MDText.com, Inc., South Dartmouth (MA), 2000).
- 48. Barrios, V. et al. Pregnancy-Associated Plasma Protein (PAPP)-A2 in Physiology and
- 817 Disease. Cells 10, 3576 (2021).
- 49. Overgaard, M. T. et al. Pregnancy-associated Plasma Protein-A2 (PAPP-A2), a Novel
- Insulin-like Growth Factor-binding Protein-5 Proteinase. *J. Biol. Chem.* **276**, 21849–21853
- 820 (2001).
- 50. Tóth, E. *et al.* Decreased Expression of Placental Proteins in Recurrent Pregnancy Loss:
- Functional Relevance and Diagnostic Value. Int. J. Mol. Sci. 25, 1865 (2024).
- 51. Hattersley, A. T. & Tooke, J. E. The fetal insulin hypothesis: an alternative explanation of
- the association of low birthweight with diabetes and vascular disease. *Lancet Lond. Engl.*
- **353**, 1789–1792 (1999).
- 52. Rother, K. I. & Accili, D. Role of insulin receptors and IGF receptors in growth and
- 827 development. *Pediatr. Nephrol.* **14**, 558–561 (2000).
- 53. Gardner, E. J. et al. Damaging missense variants in IGF1R implicate a role for IGF-1

resistance in the etiology of type 2 diabetes. *Cell Genomics* **2**, None (2022).

- 54. Solomon-Zemler, R. et al. A novel heterozygous IGF-1 receptor mutation associated with
- hypoglycemia. *Endocr. Connect.* **6**, 395–403 (2017).
- 55. Thompson, W. D. et al. Fetal alleles predisposing to metabolically favorable adiposity are
- associated with higher birth weight. *Hum. Mol. Genet.* **31**, 1762–1775 (2022).
- 56. Bianco, M. E. *et al.* Hyperglycemia and Adverse Pregnancy Outcome Follow-Up Study:
- newborn anthropometrics and childhood glucose metabolism. *Diabetologia* **64**, 561–570
- 836 (2021).
- 57. Adams, M. et al. Activators of peroxisome proliferator-activated receptor gamma have
- depot-specific effects on human preadipocyte differentiation. J. Clin. Invest. **100**, 3149–3153
- **839** (1997).
- 58. Altshuler, D. *et al.* The common PPARgamma Pro12Ala polymorphism is associated with
  decreased risk of type 2 diabetes. *Nat. Genet.* 26, 76–80 (2000).
- 59. Udler, M. S. et al. Type 2 diabetes genetic loci informed by multi-trait associations point
- to disease mechanisms and subtypes: A soft clustering analysis. *PLOS Med.* **15**, e1002654
  (2018).
- 60. Liu, X. *et al.* Variants in the fetal genome near pro-inflammatory cytokine genes on 2q13
  associate with gestational duration. *Nat. Commun.* **10**, 3927 (2019).
- 61. Gulcher, J. R., Kristjánsson, K., Gudbjartsson, H. & Stefánsson, K. Protection of privacy
- by third-party encryption in genetic research in Iceland. *Eur. J. Hum. Genet. EJHG* 8,
- 849 739–742 (2000).
- 62. Li, H. A statistical framework for SNP calling, mutation discovery, association mapping
- and population genetical parameter estimation from sequencing data. *Bioinforma. Oxf. Engl.*27, 2987–2993 (2011).
- 63. McLaren, W. et al. The Ensembl Variant Effect Predictor. Genome Biol. 17, 122 (2016).
- 64. Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in

- 855 141,456 humans. *Nature* **581**, 434–443 (2020).
- 65. Rentzsch, P., Witten, D., Cooper, G. M., Shendure, J. & Kircher, M. CADD: predicting the
- deleteriousness of variants throughout the human genome. *Nucleic Acids Res.* 47,
- 858 D886–D894 (2019).
- 66. Loh, P.-R. *et al.* Efficient Bayesian mixed-model analysis increases association power in
- 860 large cohorts. Nat. Genet. 47, 284–290 (2015).
- 67. Bycroft, C. et al. The UK Biobank resource with deep phenotyping and genomic data.
- 862 Nature 562, 203–209 (2018).
- 68. Mbatchou, J. *et al.* Computationally efficient whole-genome regression for quantitative
- and binary traits. *Nat. Genet.* **53**, 1097–1103 (2021).
- 69. Ioannidis, N. M. et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of
- 866 Rare Missense Variants. Am. J. Hum. Genet. 99, 877–885 (2016).
- 70. Purcell, S. et al. PLINK: A Tool Set for Whole-Genome Association and
- Population-Based Linkage Analyses. Am. J. Hum. Genet. 81, 559–575 (2007).
- 71. Hawkes, G. *et al.* Genetic evidence that high BMI in childhood has a protective effect on
- intermediate diabetes traits, including measures of insulin sensitivity and secretion, after
- accounting for BMI in adulthood. *Diabetologia* 66, 1472–1480 (2023).
- 72. Boughton, A. P. et al. LocusZoom.js: interactive and embeddable visualization of genetic
- association study results. *Bioinforma. Oxf. Engl.* **37**, 3017–3018 (2021).
- 73. Kolberg, L., Raudvere, U., Kuzmin, I., Vilo, J. & Peterson, H. gprofiler2 -- an R package
- for gene list functional enrichment analysis and namespace conversion toolset g:Profiler.
- 876 *F1000Research* **9**, ELIXIR-709 (2020).
- 74. Kong, A. et al. Detection of sharing by descent, long-range phasing and haplotype
- imputation. *Nat. Genet.* **40**, 1068–1075 (2008).
- 879 75. Gudbjartsson, D. F. et al. Large-scale whole-genome sequencing of the Icelandic
- 880 population. Nat. Genet. 47, 435–444 (2015).

- 76. Eggertsson, H. P. *et al.* GraphTyper2 enables population-scale genotyping of structural
- variation using pangenome graphs. *Nat. Commun.* **10**, 5402 (2019).
- 77. Delaneau, O., Zagury, J.-F., Robinson, M. R., Marchini, J. L. & Dermitzakis, E. T.
- Accurate, scalable and integrative haplotype estimation. *Nat. Commun.* **10**, 5436 (2019).
- 78. Halldorsson, B. V. et al. The sequences of 150,119 genomes in the UK Biobank. Nature
- **607**, 732–740 (2022).
- 79. Mirshahi, U. L. *et al.* Reduced penetrance of MODY-associated HNF1A/HNF4A variants
- but not GCK variants in clinically unselected cohorts. *Am. J. Hum. Genet.* **109**, 2018–2028
- 889 (2022).